ReviewBritish journal of haematology2007
Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model.
Review in British journal of haematology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 59 citations in OpenAlex.
- MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.Molecular cancer · 2010Trial
- The multiple functions of CD5 in diseases related to immune disorders.Annals of medicine · 2025Review
- The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia.Blood cancer journal · 2024Article
- Age-related accumulation of B-1 cell progenitors in mice reflects changes in miR15a/16-1 expression and radioresistance capacity.Experimental hematology & oncology · 2023Article
- Review
- Knockout of both miR-15/16 loci induces acute myeloid leukemia.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Overview of the Use of Murine Models in Leukemia and Lymphoma Research.Frontiers in oncology · 2017Review
- Animal Models to Study MicroRNA Function.Advances in cancer research · 2017Review
- Role of mir-15a/16-1 in early B cell development in a mouse model of chronic lymphocytic leukemia.Oncotarget · 2016Article
- Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade.Seminars in oncology · 2016Review
- Article
- Article
- Antibody-based therapeutics for the treatment of human B cell malignancies.Current allergy and asthma reports · 2013Review
- Cell-to-cell miRNA transfer: from body homeostasis to therapy.Pharmacology & therapeutics · 2012Review
- Aberrant microRNA expression and its implications in the pathogenesis of leukemias.Cellular oncology (Dordrecht, Netherlands) · 2012Review
- Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia.Genes and immunity · 2012Article
- Article
- The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases.Journal of molecular biology · 2010Review
- Systemic lupus erythematosus and increased risk to develop B cell malignancies: role of the p200-family proteins.Immunology letters · 2010Review
- MicroRNA in the adaptive immune system, in sickness and in health.Journal of clinical immunology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Mouse models are valuable tools in the study of human chronic lymphocytic leukaemia (CLL). The New Zealand Black (NZB) strain is a naturally occurring model of late-onset CLL characterized by B-cell hyperproliferation and autoimmunity early in life, followed by progression to CLL. Other genetically engineered models of CLL that have been developed include (NZB x NZW) F1 mice engineered to express IL5, mice expressing human TCL1A, and mice overexpressing both BCL2 and a tumour necrosis factor receptor-associated factor. The applicability to human CLL varies with each model, suggesting that CLL is a multifactorial disease. Our work with the de novo NZB model has revealed many similarities to the human situation, particularly familial CLL. In NZB, the malignant clones express CD5, zap-70, and have chromosomal instability and germline Ig sequence. We also identified a point mutation in the 3'-flanking sequence of Mirn16-1, which resulted in decreased levels of the microRNA, miR-16 in lymphoid tissue. Exogenous restoration of miR-16 to an NZB malignant B-1 cell line resulted in cell cycle alterations, suggesting that the altered expression of Mirn15a/16-1 is an important molecular lesion in CLL. Future studies utilizing the NZB mouse could ascertain the role of environmental triggers, such as low dose radiation and organic chemicals in the augmentation of a pre-existing propensity to develop CLL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.